Publications
- Importance of quantitative evaluations of BCR-ABL transcripts using real-time PCR for effective treatment of chronic myeloid leukemia +12006 | Faculty of Medicine in Hradec Králové
- Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic2023 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Brentuximab vedotin consolidation therapy after autologous stem cell transplantation in relapsed/refractory classic Hodgkin lymphoma patients in the Czech Republic2023 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era2023 | Faculty of Medicine in Hradec Králové
- Peripheral T-Cell Lymphomas Involving the Central Nervous System: A Report From the Czech Lymphoma Study Group Registry2022 | First Faculty of Medicine, Second Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové, Central Library of Charles University
- Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world2022 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen
- Burkitt lymphoma-a retrospective analysis of data from the Registry of the Czech Lymphoma Study Group with external validation of the Burkitt lymphoma International Prognostic Index2022 | First Faculty of Medicine, Second Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Léčba starších nemocných s Hodgkinovým lymfomem - rok 20222022 | Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Rituximab, Cyclophosphamide and Dexamethasone (RCD) Chemoimmunotherapy for Relapsed Chronic Lymphocytic Leukaemia2021 | Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 study2021 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
Loading network view...